
Opinion|Videos|April 17, 2025
Patient Communication and Treatment Adherence in NMIBC
Experts discuss the potential impact of FDA-approved novel delivery systems on patients’ quality of life and treatment adherence in the management of non–muscle-invasive bladder cancer (NMIBC).
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If they are FDA approved, what impact are the novel delivery systems likely to have on patients’ quality of life? Treatment adherence?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5


















